SCHEMBL801650

SCHEMBL801650

Cc1ccccc1-c1cc(NCCN)cc(Nc2n[nH]c3ccccc23)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 2/20 0.41
TRPA1 O75762 1/20 0.38
GRM4 Q14833 2/20 0.38
KARS1 Q15046 1/20 0.36
PIM1 P11309 2/20 0.36
PIM3 Q86V86 2/20 0.36
PIM2 Q9P1W9 2/20 0.36
CDK7 P50613 1/20 0.35
PRKCH P24723 1/20 0.34
PRKCE Q02156 1/20 0.34
KDM4E B2RXH2 1/20 0.34
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
MTOR P42345 1/20 0.34
PIK3CG P48736 1/20 0.34
ADRA2A P08913 2/20 0.34
ROCK2 O75116 1/20 0.34
ROCK1 Q13464 1/20 0.34
PKN2 Q16513 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL805539 0.86 ACP1 (0.39) FADS1TRPA1GRM4ITKAURKB
SCHEMBL802280 0.82 FADS1 (0.42) FADS1TRPA1GRM4PIK3CDPIK3CA
SCHEMBL802685 0.81 GRM4 (0.39) FADS1TRPA1GRM4PIM1PIM3
SCHEMBL802348 0.79 FADS1 (0.40) FADS1TRPA1GRM4KDM4EPIK3CD
SCHEMBL802326 0.77 FADS1 (0.48) FADS1TRPA1GRM4KDM4EPIK3CD
SCHEMBL802027 0.76 FADS1 (0.46) FADS1TRPA1GRM4KDM4EADRA2A
SCHEMBL13962987 0.75 CYP1A2 (0.42) FADS1TRPA1KDM4E
SCHEMBL801684 0.74 EGFR (0.39) FADS1TRPA1GRM4ADRA2AROCK2
SCHEMBL802674 0.74 GSK3A (0.44) FADS1TRPA1GRM4PIK3CDPIK3CA
SCHEMBL802062 0.73 CYP1A2 (0.43) PIM1PIM3PIM2ADRA2AAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 FADS1 3442/4885TRPA1 4786/4885GRM4 3726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.